{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:07:31Z","timestamp":1790784451756,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T00:00:00Z","timestamp":1653523200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005614","name":"BC Cancer Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Methods & Clinical Development"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.omtm.2022.05.006","type":"journal-article","created":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T09:38:05Z","timestamp":1653817085000},"page":"4-14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Selective B cell depletion upon intravenous infusion of replication-incompetent anti-CD19 CAR lentivirus"],"prefix":"10.1016","volume":"26","author":[{"given":"Craig M.","family":"Rive","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7328-7204","authenticated-orcid":false,"given":"Eric","family":"Yung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Dreolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher G.","family":"May","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Woodsworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7259-1247","authenticated-orcid":false,"given":"Robert A.","family":"Holt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2022.05.006_bib1","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-Cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2022.05.006_bib2","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2022.05.006_bib3","doi-asserted-by":"crossref","unstructured":"Park JH, Rivi\u00e8re I, Gonen M, Wang X, S\u00e9n\u00e9chal B, Curran KJ, Sauter C, Wang Y, Santomasso B, Mead E, et\u00a0al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N. Engl. J. Med. 2018 Feb 1;378(5):449\u2013459.","DOI":"10.1056\/NEJMoa1709919"},{"key":"10.1016\/j.omtm.2022.05.006_bib4","doi-asserted-by":"crossref","unstructured":"Hay KA, Gauthier J, Hirayama AV, Voutsinas JM, Wu Q, Li D, Gooley TA, Cherian S, Chen X, Pender BS, et\u00a0al. Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. Blood. 2019 Apr 11;133(15):1652\u20131663.","DOI":"10.1182\/blood-2018-11-883710"},{"key":"10.1016\/j.omtm.2022.05.006_bib5","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1182\/blood.2019000905","article-title":"High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy","volume":"134","author":"Hirayama","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2022.05.006_bib6","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T Cells in refractory B-Cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2022.05.006_bib7","first-page":"98","article-title":"Risks and benefits of chimeric antigen receptor T-cell (CAR-T) therapy in cancer: a systematic review and meta-analysis","volume":"33","author":"Grigor","year":"2019"},{"key":"10.1016\/j.omtm.2022.05.006_bib8","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.ymthe.2019.04.001","article-title":"Preclinical evaluation of allogeneic CAR T\u00a0cells targeting BCMA for the treatment of multiple myeloma","volume":"27","author":"Sommer","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2022.05.006_bib9","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaj2013","article-title":"Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T\u00a0cells","volume":"9","author":"Qasim","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtm.2022.05.006_bib10","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2015.64.5929","article-title":"Allogeneic T\u00a0cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease","volume":"34","author":"Brudno","year":"2016","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omtm.2022.05.006_bib11","doi-asserted-by":"crossref","first-page":"89256","DOI":"10.18632\/oncotarget.19204","article-title":"A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy","volume":"8","author":"Williams","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.omtm.2022.05.006_bib12","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/nmeth.4258","article-title":"Progenitor T-cell differentiation from hematopoietic stem cells using Delta-like-4 and VCAM-1","volume":"14","author":"Shukla","year":"2017","journal-title":"Nat. Methods"},{"key":"10.1016\/j.omtm.2022.05.006_bib13","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nnano.2017.57","article-title":"In situ programming of leukaemia-specific T\u00a0cells using synthetic DNA nanocarriers","volume":"12","author":"Smith","year":"2017","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.omtm.2022.05.006_bib14","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41586-019-1546-z","article-title":"Targeting cardiac fibrosis with engineered T\u00a0cells","volume":"573","author":"Aghajanian","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.omtm.2022.05.006_bib15","doi-asserted-by":"crossref","first-page":"e9158","DOI":"10.15252\/emmm.201809158","article-title":"In\u00a0vivo generation of human CD 19- CAR T\u00a0cells results in B-cell depletion and signs of cytokine release syndrome","volume":"10","author":"Pfeiffer","year":"2018","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.omtm.2022.05.006_bib16","first-page":"5702","article-title":"Combining T-cell-specific activation and in\u00a0vivo gene delivery through CD3-targeted lentiviral vectors","volume":"4","author":"Frank","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.omtm.2022.05.006_bib17","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/j.ymthe.2020.05.005","article-title":"In\u00a0vivo generation of CAR T\u00a0cells selectively in human CD4+ lymphocytes","volume":"28","author":"Agarwal","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2022.05.006_bib18","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/sj.leu.2403302","article-title":"Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia","volume":"18","author":"Imai","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.omtm.2022.05.006_bib19","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0161-5890(97)00144-2","article-title":"Construction and characterisation of a functional CD19 specific single chain Fv fragment for immunotherapy of B lineage leukaemia and lymphoma","volume":"34","author":"Nicholson","year":"1997","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.omtm.2022.05.006_bib20","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1182\/blood-2010-01-265041","article-title":"Adoptive transfer of syngeneic T\u00a0cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells","volume":"116","author":"Kochenderfer","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2022.05.006_bib21","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1002\/eji.200635874","article-title":"Unidirectional development of CD8+ central memory T\u00a0cells into protective Listeria-specific effector memory T\u00a0cells","volume":"36","author":"Huster","year":"2006","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.omtm.2022.05.006_bib22","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.4049\/jimmunol.175.7.4686","article-title":"Functional properties and lineage relationship of CD8+ T\u00a0cell subsets identified by expression of IL-7 receptor alpha and CD62L","volume":"175","author":"Bachmann","year":"2005","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.omtm.2022.05.006_bib23","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/BF01788960","article-title":"In\u00a0vitro and in\u00a0vivo antitumor activity of a chimeric anti-CD19 antibody.","volume":"41","author":"Pietersz","year":"1995","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.omtm.2022.05.006_bib24","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1097\/CJI.0b013e3181ac6138","article-title":"Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor","volume":"32","author":"Kochenderfer","year":"2009","journal-title":"J.\u00a0Immunother."},{"key":"10.1016\/j.omtm.2022.05.006_bib25","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13045-017-0437-8","article-title":"Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T\u00a0cells","volume":"10","author":"Qin","year":"2017","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.omtm.2022.05.006_bib26","doi-asserted-by":"crossref","first-page":"E459","DOI":"10.1073\/pnas.1524155113","article-title":"Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies","volume":"113","author":"Rodgers","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U\u00a0S\u00a0A"},{"key":"10.1016\/j.omtm.2022.05.006_bib27","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/leu.2015.247","article-title":"Chimeric antigen receptor-modified T\u00a0cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in\u00a0vivo","volume":"30","author":"Sommermeyer","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.omtm.2022.05.006_bib28","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.1021\/acs.biochem.9b00808","article-title":"Fine epitope mapping of the CD19 extracellular domain promotes design","volume":"58","author":"Klesmith","year":"2019","journal-title":"Biochemistry"},{"key":"10.1016\/j.omtm.2022.05.006_bib29","doi-asserted-by":"crossref","first-page":"12537","DOI":"10.1128\/JVI.78.22.12537-12547.2004","article-title":"Murine T\u00a0cells potently restrict human immunodeficiency virus infection","volume":"78","author":"Baumann","year":"2004","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omtm.2022.05.006_bib30","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/CJI.0b013e3182187600","article-title":"Genetic engineering of murine CD8+ and CD4+ T\u00a0cells for preclinical adoptive immunotherapy studies","volume":"34","author":"Kerkar","year":"2011","journal-title":"J.\u00a0Immunother."},{"key":"10.1016\/j.omtm.2022.05.006_bib31","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1128\/JVI.00870-06","article-title":"Nuclear import of the preintegration complex is blocked upon infection by human immunodeficiency virus type 1 in mouse cells","volume":"81","author":"Tsurutani","year":"2007","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omtm.2022.05.006_bib32","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.omtm.2018.08.002","article-title":"A nontoxic transduction enhancer enables highly efficient lentiviral transduction of primary murine T\u00a0cells and hematopoietic stem cells","volume":"10","author":"Delville","year":"2018","journal-title":"Mol Ther - Methods Clin Dev."},{"key":"10.1016\/j.omtm.2022.05.006_bib33","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1182\/blood-2003-09-3217","article-title":"Targeting lentiviral vector expression to hepatocytes limits transgene-specific immune response and establishes long-term expression of human antihemophilic factor IX in mice","volume":"103","author":"Follenzi","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2022.05.006_bib34","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1006\/mthe.2002.0630","article-title":"Biodistribution and toxicity studies of VSVG-pseudotyped lentiviral vector after intravenous administration in mice with the observation of in\u00a0vivo transduction of bone marrow","volume":"6","author":"Pan","year":"2002","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2022.05.006_bib35","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1182\/blood-2013-11-540641","article-title":"Mystery solved: VSV-G-LVs do not allow efficient gene transfer into unstimulated T\u00a0cells, B cells, and HSCs because they lack the LDL receptor","volume":"123","author":"Amirache","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2022.05.006_bib36","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1006\/mthe.2000.0116","article-title":"VSV-G pseudotyped lentiviral vector particles produced in human cells are inactivated by human serum","volume":"2","author":"DePolo","year":"2000","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2022.05.006_bib37","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","article-title":"Induction of resistance to chimeric antigen receptor T\u00a0cell therapy by transduction of a single leukemic B cell","volume":"24","author":"Ruella","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2022.05.006_bib38","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.omtm.2022.05.006_bib39","first-page":"227ra33","article-title":"Gene therapy for Wiskott-Aldrich syndrome--long-term efficacy and genotoxicity","author":"Braun","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtm.2022.05.006_bib40","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1172\/JCI35700","article-title":"Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1","volume":"118","author":"Hacein-Bey-Abina","year":"2008","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.omtm.2022.05.006_bib41","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1172\/JCI35798","article-title":"Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients","volume":"118","author":"Howe","year":"2008","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.omtm.2022.05.006_bib42","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nm1393","article-title":"Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1","volume":"12","author":"Ott","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2022.05.006_bib43","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ymgme.2003.08.016","article-title":"Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer","volume":"80","author":"Raper","year":"2003","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.omtm.2022.05.006_bib44","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/nm.2088","article-title":"Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease","volume":"16","author":"Stein","year":"2010","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2022.05.006_bib45","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.molmed.2016.02.002","article-title":"Treating immunodeficiency through HSC gene therapy","volume":"22","author":"Booth","year":"2016","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.omtm.2022.05.006_bib46","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/s41375-018-0106-0","article-title":"Clinical use of lentiviral vectors","volume":"32","author":"Milone","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.omtm.2022.05.006_bib47","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ymthe.2017.09.008","article-title":"Absence of replication-competent lentivirus in the clinic: analysis of infused T\u00a0cell products","volume":"26","author":"Cornetta","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2022.05.006_bib48","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ymthe.2017.10.012","article-title":"Retroviral and lentiviral safety analysis of gene-modified T\u00a0cell products and infused HIV and oncology patients","volume":"26","author":"Marcucci","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2022.05.006_bib49","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/nbt0997-871","article-title":"Multiply attenuated lentiviral vector achieves efficient gene delivery in\u00a0vivo","volume":"15","author":"Zufferey","year":"1997","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtm.2022.05.006_bib50","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1126\/science.272.5259.263","article-title":"In\u00a0vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector","volume":"272","author":"Naldini","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.omtm.2022.05.006_bib51","doi-asserted-by":"crossref","first-page":"8463","DOI":"10.1128\/JVI.72.11.8463-8471.1998","article-title":"A third-generation lentivirus vector with a conditional packaging system","volume":"72","author":"Dull","year":"1998","journal-title":"J.\u00a0Virol."}],"container-title":["Molecular Therapy - Methods & Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050122000717?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050122000717?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T20:12:14Z","timestamp":1714680734000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050122000717"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":51,"alternative-id":["S2329050122000717"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2022.05.006","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.05.15.098335","asserted-by":"object"}]},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Selective B cell depletion upon intravenous infusion of replication-incompetent anti-CD19 CAR lentivirus","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2022.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors.","name":"copyright","label":"Copyright"}]}}